Associations - BIRC3 mutation

BIRC3 mutation BIRC3 mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	BIRC3 mutation BIRC3 mutation	Small Lymphocytic Lymphoma Small Lymphocytic Lymphoma	ibrutinib Sensitive: B - Late Trials	ibrutinib Sensitive: B - Late Trials
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	ibrutinib Sensitive: B - Late Trials	ibrutinib Sensitive: B - Late Trials
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	obinutuzumab Resistant: B - Late Trials	obinutuzumab Resistant: B - Late Trials
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	rituximab Resistant: C3 – Early Trials	rituximab Resistant: C3 – Early Trials
BIRC3 mutation BIRC3 mutation	Mantle Cell Lymphoma Mantle Cell Lymphoma	BIRC3 mutation BIRC3 mutation	Mantle Cell Lymphoma Mantle Cell Lymphoma	temsirolimus Resistant: C3 – Early Trials	temsirolimus Resistant: C3 – Early Trials
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	FCR Resistant: C3 – Early Trials	FCR Resistant: C3 – Early Trials
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BR Resistant: C3 – Early Trials	BR Resistant: C3 – Early Trials
BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	BIRC3 mutation BIRC3 mutation	Chronic Lymphocytic Leukemia CLL	DC-1-192 Sensitive: D – Preclinical	DC-1-192 Sensitive: D – Preclinical